Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A follow-up study of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients

Next Previous
X
Search
Trial Profile

A follow-up study of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 Oct 2017 Results from a subset of initially randomized 36 patients (n = 19) presented in an ASIT Biotech media release.
    • 24 Oct 2017 According to an ASIT Biotech media release, this trial was performed at the Carl Gustav Carus University Hospital in Dresden, Germany.
    • 24 Oct 2017 Status changed from planning to active, no longer recruiting, according to an ASIT Biotech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top